Filter results
You can narrow down the results using the filters
Topic
- Advisory bodies and committees (213)
- Medical devices (75)
- Scheduling (national classification system) (55)
- Medicines (44)
- Non-prescription medicines (18)
- Advertising (17)
- Registered complementary medicines (17)
- Therapeutic goods regulation (17)
- Complementary medicines (15)
- Unique Device Identification (UDI) Hub (15)
- COVID-19 vaccines (14)
- In Vitro Diagnostic medical devices (IVDs) (13)
- Biologicals (12)
- Regulatory compliance (12)
- Prescription medicines (10)
- Medicinal cannabis hub (5)
- Biological medicines (4)
- Over the counter medicine (4)
- Unapproved therapeutic goods (4)
- Medical devices safety (3)
- Medicines safety (3)
- Manufacturing (2)
- Safety (2)
- Advanced therapies (1)
- Clinical trials (1)
- Legislation (1)
- Listed medicines (1)
- Other therapeutic goods (1)
- Pharmacovigilance (1)
- Shortages (1)
Search
308 result(s) found, displaying 1 to 25
- Committee meetingsACMD meeting #73, 8 June 2023Advisory Committee on Medical Devices (ACMD) meeting
- WebinarsUnique Device Identification Webinar #16 - The value of UDI for procurement and inventory management in hospitalsUDI Webinar 16 – Australian UDI update and guest speakers on the value of UDI for procurement and inventory management in hospitals.
- Committee meetingsACCM meeting #31, 20 April 2023Advisory Committee on Complementary Medicines (ACCM) meeting
- Committee meetingsACMD meeting #72, 13 April 2023Advisory Committee on Medical Devices (ACMD) meeting
- Committee meetingsWHPWG meeting #3, March 2023The 3rd meeting of the Women's Health Product Working Group (WHPWG #3), March 2023
- WorkshopsGMP Forum 2023The TGA Good Manufacturing Practice Forum returned to Sydney on 21 March 2023.
- PresentationsWebinar presentation: Change to classification of MDMA and psilocybin to enable prescribing by authorised psychiatristsThis webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be conditionally classified as Schedule 8 (controlled drug) in the Poisons Standard.
- WebinarsChange to classification of MDMA and psilocybin to enable prescribing by authorised psychiatristsThis webinar will address the recent announcement by the TGA that medicines containing psilocybin and MDMA will be classified as Schedule 8 (controlled drug) when prescribed by a psychiatrist.
- WebinarsUnique Device Identification Webinar #15 - UDI in the Healthcare System: Considerations, Challenges and ImplementationIn this webinar we will provide an update on the Australian UDI implementation and discuss the challenges and benefits of having UDI in healthcare and the role of hospitals and other healthcare providers in relation to using UDI.
- Committee meetingsACMD meeting #71, 9 February 2023Advisory Committee on Medical Devices (ACMD) meeting
- PresentationsMedicinal Cannabis Reforms, complying with Therapeutic Goods (Standard for Medicinal Cannabis) (TGO 93) Order 2017This webinar will explain labelling requirements for finished MCP in detail.
- Committee meetingsWHPWG meeting #2, October 2022The 2nd meeting of the Women's Health Product Working Group (WHPWG #2), October 2022
- WebinarsWebinar: Risks of intentional self-poisoning with paracetamol: key independent expert findings and consultation on possible access and purchasing controlsUnderstand the key findings of the independent expert report on the risks of intentional self-poisoning with paracetamol and have your questions answered about the TGA’s consultation (starting mid-September) on the possible options for changing access or purchasing controls through the Poisons Standard.
- PresentationsUnique Device Identification Webinar #12 - Q&A on the AusUDID Sandpit and information about UDI Consultation Paper 3Information for manufacturers, sponsors and users of the UDI data on how to access the AusUDID Sandpit
- PresentationsMedicinal Cannabis Fees and Charges Information SessionThis webinar will guide you through the process of charging for regulatory activities, the medicinal cannabis funding model and the fees and charges structure and amounts proposed to commence on 1 July 2023.
- WebinarsEU MDR transition webinar #3 – consent to supply and market notificationsThe final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.
- PresentationsWebinar presentation: EU MDR Transition - consent to supply and market notificationsThe final webinar in this series will explore the impact changes to the EU MDR will have on consent to supply and market notifications.
Pages
- Current page 1
- Page 2
- Page 3
- Page 4
- Page 5
- Page 6
- Page 7
- Page 8
- Page 9
- …
- Next page Next ›
- Last page Last »